Familial hyperaldosteronism IIII

Hormone and Metabolic Research

Volumn 42, Issue 6, 2010, Pages 424-428

  Quack, I ^a   Vonend, O ^a   Rump, L C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adrenal glands; Familial hyperaldosteronism; Hyperaldosteronism; Hypertension; Mendelian; Primary aldosteronism

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; AMILORIDE; CORTICOTROPIN; DEXAMETHASONE; MINERALOCORTICOID ANTAGONIST; STEROID 11BETA MONOOXYGENASE;

ADRENAL DISEASE; ADRENAL HYPERTROPHY; ALDOSTERONE RELEASE; CLINICAL FEATURE; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC TEST; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; FAMILIAL HYPERALDOSTERONE 1; FAMILIAL HYPERALDOSTERONISM; FAMILIAL HYPERALDOSTERONISM 1; FAMILIAL HYPERALDOSTERONISM 2; FAMILIAL HYPERALDOSTERONISM 3; FAMILY HISTORY; FAMILY STUDY; HUMAN; HYPERTENSION; INHERITANCE; PATHOGENESIS; PHENOTYPE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ALGORITHM; CLASSIFICATION; ENDOCRINE SYSTEM EXAMINATION; FAMILY; GENETIC SCREENING; GENETICS; HYPERALDOSTERONISM;

ALGORITHMS; DIAGNOSTIC TECHNIQUES, ENDOCRINE; FAMILY; GENETIC TESTING; HUMANS; HYPERALDOSTERONISM; HYPERTENSION;

EID: 77952941249     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1246187     Document Type: Review

References (43)

1. Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol 2008 21 447-454
2. Loffing J, Korbmacher C. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflugers Arch 2009 458 111-135
3. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009 308 53-62
4. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab 2009 94 1191-1197
5. Staermose S, Marwick TH, Gordon RD, Cowley D, Dowling A, Stowasser M. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. Hypertension 2009 53 e31-e32
6. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009 94 1125-1130
7. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human Mendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab 2008 93 3117-3123
8. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr. WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008 93 3266-3281
9. Quack I, Vonend O, Sellin L, Stegbauer J, Dekomien G, Rump LC. A tale of two patients with Mendelian hypertension. Hypertension 2008 51 609-614
10. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966 95 1109-1119
11. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991 18 283-286
12. Lifton RP, Dluhy RG, Powers M, Ulick S, Lalouel JM. The molecular basis of glucocorticoid-remediable aldosteronism, a Mendelian cause of human hypertension. Trans Assoc Am Physicians 1992 105 64-71
13. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992 19 319-322
14. Mulatero P. A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III. J Clin Endocrinol Metab 2008 93 2972-2974
15. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992 355 262-265
16. Miyahara K, Kawamoto T, Mitsuuchi Y, Toda K, Imura H, Gordon RD, Shizuta Y. The chimeric gene linked to glucocorticoid-suppressible hyperaldosteronism encodes a fused P-450 protein possessing aldosterone synthase activity. Biochem Biophys Res Commun 1992 189 885-891
17. Stowasser M, Gartside MG, Taylor WL, Tunny TJ, Gordon RD. In familial hyperaldosteronism type I, hybrid gene-induced aldosterone production dominates that induced by wild-type genes. J Clin Endocrinol Metab 1997 82 3670-3676
18. Ulick S, Chan CK, Gill Jr. JR, Gutkin M, Letcher L, Mantero F, New MI. Defective fasciculata zone function as the mechanism of glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab 1990 71 1151-1157
19. Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis. Horm Metab Res 2008 40 435-441
20. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000 85 2160-2166
21. Gates LJ, MacConnachie AA, Lifton RP, Haites NE, Benjamin N. Variation of phenotype in patients with glucocorticoid remediable aldosteronism. J Med Genet 1996 33 25-28
22. Vonend O, Altenhenne C, Buchner NJ, Dekomien G, Maser-Gluth C, Weiner SM, Sellin L, Hofebauer S, Epplen JT, Rump LC. A German family with glucocorticoid-remediable aldosteronism. Nephrol Dial Transplant 2007 22 1123-1130
23. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997 82 3570-3573
24. Malagon-Rogers M. Non-glucocorticoid-remediable aldosteronism in an infant with low-renin hypertension. Pediatr Nephrol 2004 19 235-236
25. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000 85 3313-3318
26. Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 2002 88 475-480
27. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991 83 1849-1865
28. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005 90 5070-5076
29. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 2005 23 1477-1484
30. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 2000 37 831-835
31. Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertens 2000 18 1165-1176
32. Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009 94 2437-2445
33. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, ODonnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007 49 846-856
34. Buhler FR, Bolli P, Kiowski W, Erne P, Hulthen UL, Block LH. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med 1984 77 36-42
35. Stowasser M, Gordon RD. Monogenic mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab 2006 20 401-420
36. Stowasser M, Gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol 2001 28 1087-1090
37. Greco RG, Carroll JE, Morris DJ, Grekin RJ, Melby JC. Familial hyperaldosteronism, not suppressed by dexamethasone. J Clin Endocrinol Metab 1982 55 1013-1016
38. Gagliardi L, Hotu C, Casey G, Braund WJ, Ling KH, Dodd T, Manavis J, Devitt PG, Cutfield R, Rudzki Z, Scott HS, Torpy DJ. Familial vasopressin-sensitive ACTH-independent macronodular adrenal hyperplasia (VPs-AIMAH): clinical studies of three kindreds. Clin Endocrinol (Oxf) 2009 70 883-891
39. Mulatero P, Bertello C, Verhovez A, Rossato D, Giraudo G, Mengozzi G, Limerutti G, Avenatti E, Tizzani D, Veglio F. Differential diagnosis of primary aldosteronism subtypes. Curr Hypertens Rep 2009 11 217-223
40. Luft FC. Mendelian forms of human hypertension and mechanisms of disease. Clin Med Res 2003 1 291-300
41. Martinez-Aguayo A, Fardella C. Genetics of hypertensive syndrome. Horm Res 2009 71 253-259
42. Vonend O, Rump LC. Normokalemic primary hyperaldosteronism. Dtsch Med Wochenschr 2006 131 H24-H27
43. Vonend O, Stegbauer J, Kokulinsky P, Adams S, Liermann D, Hahn K, Rump LC. Comparison of adrenal imaging and selective adrenal vein sampling in primary hyperaldosteronism. Dtsch Med Wochenschr 2007 132 2436-2441